Cantargia (7V3) Stock Overview
A biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
7V3 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Cantargia AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.34 |
| 52 Week High | SEK 0.56 |
| 52 Week Low | SEK 0.064 |
| Beta | 1.76 |
| 1 Month Change | -6.11% |
| 3 Month Change | -22.77% |
| 1 Year Change | 277.48% |
| 3 Year Change | -41.45% |
| 5 Year Change | -89.67% |
| Change since IPO | -78.68% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7V3 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -4.8% | -1.1% | 2.9% |
| 1Y | 277.5% | 4.6% | 12.1% |
Return vs Industry: 7V3 exceeded the German Biotechs industry which returned 4.6% over the past year.
Return vs Market: 7V3 exceeded the German Market which returned 12.1% over the past year.
Price Volatility
| 7V3 volatility | |
|---|---|
| 7V3 Average Weekly Movement | 11.6% |
| Biotechs Industry Average Movement | 9.2% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in DE Market | 13.7% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: 7V3's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 7V3's weekly volatility has decreased from 54% to 12% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 22 | Hilde Steineger | cantargia.com |
Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in phase 1 clinical trial for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It also develops CANxx, an IL1RAP-based antibody platform.
Cantargia AB (publ) Fundamentals Summary
| 7V3 fundamental statistics | |
|---|---|
| Market cap | €89.57m |
| Earnings (TTM) | €13.51m |
| Revenue (TTM) | €29.11m |
Is 7V3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7V3 income statement (TTM) | |
|---|---|
| Revenue | SEK 316.70m |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 316.70m |
| Other Expenses | SEK 169.73m |
| Earnings | SEK 146.97m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 19, 2026
| Earnings per share (EPS) | 0.59 |
| Gross Margin | 100.00% |
| Net Profit Margin | 46.41% |
| Debt/Equity Ratio | 0% |
How did 7V3 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/12 10:46 |
| End of Day Share Price | 2026/04/10 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cantargia AB (publ) is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Arvid Necander | Carnegie Investment Bank AB |
| Soo Romanoff | Edison Investment Research |
| Sara Nik | H.C. Wainwright & Co. |